November 18, 2019
TIME on Wednesday released its first TIME 100 Next list, naming the 100 "rising stars who are shaping the future of business, entertainment, sports, politics, science, health, and more."
FDA for the first time has approved an experiment that involves temporarily transplanting pig tissue into humans, a move that experts say could lead to further developments in animal-to-human donations.
November 15, 2019
Harvard Business Review recently released its annual ranking of the 100 "Best-Performing CEOs in the World"—and the list includes nine CEOs in the health care industry.
November 11, 2019
A Florida detective at a recent police conference announced that a judge had approved a warrant to search the genetic profiles of almost one million users on the genetic database GEDmatch—news that alarms privacy advocates, who fear that warrants like this could lead to all genetic databases becoming open to law enforcement.
A Colombian woman's family history and genetic profile indicated she would develop Alzheimer's disease by the time she was 50, but researchers say an extremely rare genetic mutation staved off cognitive decline until her 70s, opening up the possibility for a new approach to Alzheimer's treatment.
November 7, 2019
NIH and the FBI are investigating nearly 200 cases involving scientists who allegedly stole biomedical research from U.S. institutions, including prestigious medical schools, for China and other countries.
October 31, 2019
TIME recently rounded up 12 innovations that will transform "medicine at a remarkable pace" over the next decade, including drone-delivered medical supplies and a stem-cell cure for diabetes.
October 15, 2019
Eight-year-old Mila Makovec was diagnosed with a rare, usually fatal neurological disorder in 2016, but now—thanks to a drug that researchers developed specifically for her—many of Mila's symptoms have been halted or reversed, according to a report published Wednesday in the New England Journal of Medicine.
October 14, 2019
As DNA sequencing becomes more common, providers face a dilemma over how much information they should reveal to their patients about their risks for untreatable conditions.
FDA on Wednesday took another step toward advancing so-called "precision medicine" by finalizing guidance detailing how drugmakers developing cancer drugs can incorporate risk assessments from unapproved diagnostic tests into their clinical trial applications.
Advisory Board. All rights reserved.